- Title: Subtitle
- 10 - Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)
- Creators
- Caron A. JacobsonFrederick L. LockeArmin GhobadiDavid B. MiklosLazaros J. LekakisOlalekan O. OluwoleYi LinBrian T. HillJohn M. TimmermanAbhinav DeolPatrick M. ReaganPatrick StiffIan W. FlinnUmar FarooqAndre H. GoyJavier MuñozTanya SiddiqiRhine R ShenAdrian BotJinghui DongKanwarjit SinghClare SpoonerRoshan KaralliyaddaJenny J. KimYan ZhengSattva S. Neelapu
- Resource Type
- Abstract
- Publication Details
- Transplantation and cellular therapy, Vol.28(3), pp.S9-S10
- DOI
- 10.1016/S2666-6367(22)00171-3
- ISSN
- 2666-6367
- eISSN
- 2666-6367
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 03/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362739802771
Abstract
10 - Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)
Transplantation and cellular therapy, Vol.28(3), pp.S9-S10
03/2022
DOI: 10.1016/S2666-6367(22)00171-3
Details
Metrics
29 Record Views